As the market continues to flirt with a slowing economy, another wave of earnings reports makes a splash on Wall Street today.

Bringing the noise today are drug biggie

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

and oil mavens

Texaco

( CHV) and

Chevron

( CHV).

In economic news, the

Mortgage Applications Survey and the

Consumer Comfort Index are due out today, although neither one should have much of an impact on today's market.

Expected Earnings Reports

This table includes S&P 500 companies only. Dates are as expected according to First Call/Thomson Financial, and may change. The full week's earnings calendar is published separately.

Economic Data

(

TheStreet Recommends

Forecasts are from

Reuters

. Times are Eastern. For a longer-term economic calendar and more, see

TSC's

Economic Databank.

)

  • 7 a.m.: Mortgage Applications Survey for the week ended Jan. 19. Source: Mortgage Bankers Association. Forecast: n.a.. Previous: 2800.6. Refinancing Index: Forecast: n.a. Previous: 332.9
  • 9 a.m.: Treasury buyback announcement. Source: Bureau of the Public Debt. The Treasury announces the details of tomorrow's reverse auction.
  • 1:30 p.m.: Treasury auction. Source: Bureau of the Public Debt. The Treasury announces the results of its monthly two-year note auction, at which $10 billion of securities will be sold, with bids due at 1 p.m.
  • 6:30 p.m.: Consumer Comfort Index for the week ended Jan. 20. Source: Money Magazine and ABC News. Forecast: n.a.. Previous: 16.

IPO Lockups Expiring

(TheStreet.com's

Ben Holmes, who heads

TSC's

ipoPros.com subsidiary, keeps a close eye on lockup expirations every week. For more on lockup expirations and why they matter, check out Holmes' primer on the subject. The full current lockup expiration list is published separately. For information on IPO pricings, filings and aftermarket activity, plus a calendar of upcoming IPOs, check out

TheStreet.com's

IPO data section.

)

Lockup End

Deal Name

Symbol

Lead Underwriter

1/24/01

Arena Pharmaceuticals

(ARNA:Nasdaq)

ING Barings Furman

1/24/01

Illumina

(ILMN:Nasdaq)

Goldman Sachs

1/24/01

Keryx Biopharmaceuticals

(KERX:Nasdaq)

Roth Capital Partners